Serendip innovations is a preclinical-stage biotechnology company developing an innovative nanoparticulate delivery system for active ingredients. We offer co-development partnerships and licensing of our nanotechnology for applications such as therapeutic and prophylactic vaccination or precision therapies. Our unique value proposition lies in the platform's high degree of modularity, enabling us to custom-design a new class of drugs. As a first application, Serendip aims to tackle the challenges of therapeutic vaccines in oncology by turning the platform into a high-performance immunization system to potentiate tumor antigens and trigger robust anti-tumor immune responses. In the cancer vaccine market, Serendip's particle is unique in its ability to precisely target cells of interest. In addition to the technical flexibility of the platform, Serendip's plant-based expression system allows the future drug products to be safer, more thermostable; the bioproduction being cost and time effective. Our strengths: cell-targeting, immunization, thermostability, bioproduction, modularity and custom design" title="" class="btn" data-container="body" data-html="true" data-id="251563" data-placement="top" data-toggle="popover" data-trigger="focus" style="color:#0077b5" tabindex="0" data-original-title="Serendip innovations"> 1,059
Activities
Technologies
Entity types
Location
12 Rue du Général-Zimmer, 67000 Strasbourg, France
Strasbourg
France
Employees
Scale: 2-10
Estimated: 11
Engaged corporates
4Added in Motherbase
3 weeks, 6 days agoDevelopment of a nanoparticulate drug delivery system. The high index of modularity allows custom design of medicines.
Serendip innovations is a preclinical-stage biotechnology company developing an innovative nanoparticulate delivery system for active ingredients. We offer co-development partnerships and licensing of our nanotechnology for applications such as therapeutic and prophylactic vaccination or precision therapies. Our unique value proposition lies in the platform's high degree of modularity, enabling us to custom-design a new class of drugs.
As a first application, Serendip aims to tackle the challenges of therapeutic vaccines in oncology by turning the platform into a high-performance immunization system to potentiate tumor antigens and trigger robust anti-tumor immune responses. In the cancer vaccine market, Serendip's particle is unique in its ability to precisely target cells of interest.
In addition to the technical flexibility of the platform, Serendip's plant-based expression system allows the future drug products to be safer, more thermostable; the bioproduction being cost and time effective.
Our strengths: cell-targeting, immunization, thermostability, bioproduction, modularity and custom design
Biotechnology, Plant-based Bioproduction, Customised vaccines, Immunology, Oncology, Nanoparticulate drug delivery system, Modularity and custom design, and Cell-targeting
Development of a nanoparticulate drug delivery system. The high index of modularity allows custom design of medicines.
Serendip innovations is a preclinical-stage biotechnology company developing an innovative nanoparticulate delivery system for active ingredients. We offer co-development partnerships and licensing of our nanotechnology for applications such as therapeutic and prophylactic vaccination or precision therapies. Our unique value proposition lies in the platform's high degree of modularity, enabling us to custom-design a new class of drugs.
As a first application, Serendip aims to tackle the challenges of therapeutic vaccines in oncology by turning the platform into a high-performance immunization system to potentiate tumor antigens and trigger robust anti-tumor immune responses. In the cancer vaccine market, Serendip's particle is unique in its ability to precisely target cells of interest.
In addition to the technical flexibility of the platform, Serendip's plant-based expression system allows the future drug products to be safer, more thermostable; the bioproduction being cost and time effective.
Our strengths: cell-targeting, immunization, thermostability, bioproduction, modularity and custom design
Corporate | Type | Tweets | Articles | |
---|---|---|---|---|
![]() Kamet Ventures Venture Capital and Private Equity Principals | Kamet Ventures Venture Capital and Private Equity Principals | Other 30 Nov 2024 | | |
![]() CNRS Research, Research Services | CNRS Research, Research Services | Other 6 Jan 2025 | | |
![]() BioValley France Public business cluster, Biotechnology, French Cluster, Biotechnology Research | BioValley France Public business cluster, Biotechnology, French Cluster, Biotechnology Research | Other 14 Jun 2024 | | |
![]() SATT Ouest Valorisation Research, Startup accelerator & VC, Research Services | SATT Ouest Valorisation Research, Startup accelerator & VC, Research Services | Other 30 Nov 2024 | |